• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein

Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein

by Adam | Oct 22, 2016

Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein Scios Inc, Brown University, Amgen Clinical Immunology (2007). [ISPRI prediction of immunogenicity]
HIV vaccine development by computer assisted design: the GAIA vaccine

HIV vaccine development by computer assisted design: the GAIA vaccine

by Adam | Oct 22, 2016

Vaccine. 2005 Mar 18; 23 [7-18):2136-48.
Developing an epitope-driven tuberculosis (TB) vaccine

Developing an epitope-driven tuberculosis (TB) vaccine

by Adam | Oct 22, 2016

Vaccine. 2005 Mar 18; 23(17-18):2121-31.
Confirmation of Immunogenic Consensus Sequence HIV-1 T-cell Epitopes in Bamako, Mali and Providence, Rhode Island

Confirmation of Immunogenic Consensus Sequence HIV-1 T-cell Epitopes in Bamako, Mali and Providence, Rhode Island

by Adam | Oct 22, 2016

Human Vaccines 2006 June; 2(3), 119-128.
Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine

Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine

by Adam | Oct 22, 2016

Vaccine. 2007 Apr 20;25(16):3179-91.

Recent Posts

  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • EpiVax Seminars in Tokyo
  • The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies
  • March of the Teenage B Cells
  • EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline